Consciousness, Psilocybin, and Well-Being

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

February 19, 2025

Study Completion Date

February 19, 2025

Conditions
HealthyPsychedelic ExperiencesSleep
Interventions
DRUG

Psilocybin

The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).

DRUG

Clonidine

Clonidine will be administered orally in a 0.2mg dose

OTHER

Saline

The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.

Trial Locations (1)

53715

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
collaborator

Usona Institute

OTHER

collaborator

Tiny Blue Dot Foundation

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT05592379 - Consciousness, Psilocybin, and Well-Being | Biotech Hunter | Biotech Hunter